Various pharmaceutical strategies aimed at addressing primary sarcopenia have been explored, including selective androgen receptor modulators [45] and the inhibition of activin receptors or myostatin through monoclonal antibodies [46]. The gene discussed is MSTN; the disease is sarcopenia.